Search results for: 'self service changes adoption'

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

The global pharmaceutical industry strives to build an inclusive partner ecosystem that integrates technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. This transformation aims to reduce the burden on investigators and sites while improving the efficiency and accuracy of adverse event (AE) tracking. Driv...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers. This analysis e...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is stron...

Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applications shaping the field. It assesses the competitive...